NASDAQ:ETON
Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc.'s revenue grew 104.9% in fiscal 2025 to $80.0M while operating margin rose to −1.1%, its highest in 7 years. Free cash flow was $10.2M, 12.7% of revenue.Summary generated from Eton Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$80.0M
Revenue growth+104.9%
Revenue, 5-yr CAGR+359.6%
Gross margin53.5%
Operating margin−1.1%
Net margin−5.8%
ROIC−1.9%
Return on equity−18.2%
Debt / equity1.17
Free cash flow$10.2M
FCF margin12.7%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 22 | 21 | 32 | 39 | 80 |
| Operating income | −1 | −8 | −1 | −3 | −1 |
| Net income | −2 | −9 | −1 | −4 | −5 |
| Free cash flow | −5 | 5 | 7 | 1 | 10 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 8-KOther events
Sep 28, 2026 - 4Insider transaction report
Aug 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KEntry into a material agreement
Aug 5, 2026 - 8-KDirector or officer change
Aug 4, 2026 - 8-KOther events
Jul 29, 2026